Mutant Staphylococcus Beta-Glucuronidase Enzymes for Rapid Drug Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current commercially available β-glucuronidase enzyme preparations for drug testing are inefficient, requiring several hours to analyze a sample due to low enzyme activity and contamination from non-BGUS proteins, leading to prolonged analysis times of at least two days.
Innovation Solution
Development of mutant β-glucuronidase enzymes with enhanced enzymatic activity and thermal stability, specifically through amino acid substitutions and additions, such as at position G563, and appending cysteine residues to the carboxy terminus, which are produced recombinantly to ensure high purity and stability, allowing for analysis in 30 minutes or less.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If commercially available BGUS enzyme preparations are used for drug testing, then the enzyme can hydrolyze glucuronides, but the analysis time is prolonged to at least two days due to low enzyme activity and contamination from non-BGUS proteins
Solution Approach 1:
The patent extracts and isolates the pure BGUS enzyme from crude commercial preparations through recombinant expression systems. By expressing the enzyme gene in suitable host organisms and purifying the recombinant protein, the invention removes contaminating non-BGUS proteins that interfere with enzyme activity and prolong analysis time, thereby achieving both high productivity and reduced analysis time
Solution Approach 2:
The patent introduces mutations in the BGUS enzyme gene to alter specific amino acid residues, thereby changing the enzyme's catalytic parameters. These parameter changes result in mutant enzymes with significantly enhanced enzymatic activity (at least 3-fold greater than wild type), which directly addresses the low productivity of commercial preparations and enables rapid analysis within 30 minutes
2Ease of manufacture
If crude extract forms of BGUS enzyme are used, then the enzyme preparation is simpler to produce, but the presence of other proteins interferes with enzyme activity and reduces efficiency
Solution Approach 1:
The patent employs self-service principles by using the host organism's own protein synthesis machinery to produce the recombinant BGUS enzyme. The enzyme gene is cloned into expression vectors that utilize the host's transcription and translation systems, eliminating the need for complex extraction and purification procedures while ensuring high purity and consistent enzyme activity
Solution Approach 2:
The invention extracts only the essential BGUS coding sequence from the complex crude extract mixture and expresses it separately in recombinant systems. This extraction of the functional enzyme component from contaminating proteins ensures reliable and consistent enzyme activity while maintaining ease of production through standardized recombinant expression protocols
3Stability of the object's composition
If wild type BGUS enzyme is used, then the enzyme maintains natural stability, but the enzymatic activity is insufficient for rapid analysis
Solution Approach 1:
The patent systematically changes the amino acid parameters of the BGUS enzyme by introducing site-directed mutations. Specific residues are mutated to alter the enzyme's catalytic efficiency and substrate binding properties, achieving at least 3-fold enhancement in enzymatic activity while maintaining structural stability through careful selection of conservative substitutions that preserve the overall protein fold and functional domains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant enzymes significantly increase analysis speed, achieving at least 3-fold greater enzymatic activity and stability, enabling rapid and accurate detection of drugs in bodily samples with reduced contamination and improved thermal stability.
Implementation Method 1
The β-glucuronidase (BGUS) enzyme catalyzes the hydrolysis of a wide variety of β-glucuronides
Data Source
AI summary
Mutated Staphylococcus sp. RLH1 β-glucuronidase enzymes with enhanced enzymatic activity and thermostability as compared to wild type enzyme are provided. The enzymes of the invention advantageously allow for accurate analysis of bodily samples for the presence of drugs in 30 minutes or less, as compared to the several hours needed using prior enzyme preparations. Methods of using the mutated enzymes for hydrolysis of glucuronide substrates, including opiates and benzodiazepines, are also provided.